- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05024149
Assessing the Impact of Electroacupuncture on Facial Thermal Characteristics of Major Depressive Disorder Patients Based on Infrared Thermal Imaging Technology
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310053
- Recruiting
- Xiaoyu Li
-
Contact:
- Xiaoyu Li
- Phone Number: +8618758240921
- Email: 673426608@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria for healthy subjects:
- Healthy subjects should provide a physical examination report within the last year, which could confirm they had not major systemic diseases, such as cardiovascular, respiratory, digestive, urinary, hematological, endocrine and neurological disease;
- 18 ≤ age ≤ 60 years, both gender;
- Subjects have clear consciousness and could communicate with others normally;
- Subjects could understand the full study protocol and written informed consent is provided by themselves. Note: Subjects who meet the above four items will be included.
Inclusion criteria for MDD patients:
- Meeting the above diagnostic criteria for MDD;
- PHQ-9 score of 5 to 14, HAMD score of 21 to 35, and a diagnosis of mild or moderate depression by a specialist; (3)18 ≤ age ≤ 60 years, both gender;
(4) Patients have clear consciousness and could communicate with others normally; (5) Patients could understand the full study protocol and written informed consent is provided by themselves; (6) Those who did not use other therapies other than the basic treatment and this experimental therapy. The basic treatment refers to basic antidepressant medications under the supervision of a specialist. The basic antidepressant medications are Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic antidepressants, Monoamine Oxidase Inhibitors. Note: Subjects who meet the above six items will be included.
Exclusion Criteria:
Exclusion criteria for healthy subjects:
- Subjects suffering from mental illness, severe depression, alcohol dependence or a history of drug abuse;
- Subjects in pregnancy, lactation or menstrual period;
- Subjects have a fever;
- Subjects have visible skin damage or scars in the face;
- Subjects participating in other trials. Note: Subjects who meet any of the above will be excluded.
Exclusion criteria for MDD patients:
- Patients with bipolar disorder;
- Patients with schizophrenia or other mental disorders;
- Patients with severe medical diseases, tumors or diseases of the central nervous system;
- Patients suffering from severe depressive episode with psychotic symptoms;
- Suicidal patients;
- Patients with seasonal depression;
- Patients with organic depression;
- Patients with alcohol or drug addicts;
- Patients using other therapies;
- Patients in pregnancy or lactation;
- Patients suffering from cognitive dysfunction, aphasia or other diseases that cannot cooperate with treatment;
- Patients with pacemakers;
- Patients who are not suitable for EA. Note: Subjects who meet any of the above will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy group
Subjects in this group will not undergo acupuncture intervention.
For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s.
In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment).
At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.
|
The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
|
Experimental: MDD electroacupuncture intervention group
|
The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
|
Experimental: MDD waiting-list group
In this study, we used a waiting list control group.
During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention.
After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.
|
The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average facial temperature
Time Frame: Change from Baseline average facial temperature at 4 weeks
|
Take the average facial temperature of 10 infrared images as the observation index, observe the change rule of the average temperature of MDD patient by comparing with healthy people.
|
Change from Baseline average facial temperature at 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infrared thermal images
Time Frame: Change from Baseline average facial temperature at 4 weeks
|
Direct contrast comparisons of the approximate distribution area of the high temperature and low temperature zone of the face between healthy subjects versus MDD patients will be done using software analyses.
|
Change from Baseline average facial temperature at 4 weeks
|
Hamilton depression scale (HAMD)
Time Frame: HAMD will be performed in the first week, the second week and the fourth week to evaluate the severity of the disease and the treatment effect.
|
This scale is performed by two trained raters to perform a Hamilton depression scale (HAMD), usually in the form of conversation and observation.
After the examination, the two raters will score independently.
HAMD score of 21 to 35 values, and higher scores mean a worse outcome.
|
HAMD will be performed in the first week, the second week and the fourth week to evaluate the severity of the disease and the treatment effect.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020YKJ04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on infrared thermography (IRT)
-
RWTH Aachen UniversityCompleted
-
Zhejiang Chinese Medical UniversityRecruitingDiabetic Peripheral NeuropathyChina
-
University Hospital, Basel, SwitzerlandCompletedGlaucomaSwitzerland
-
Thermal Diagnostics LLCActive, not recruiting
-
University Hospital, MontpellierUniversité MontpellierTerminatedDiabetic Patients Type 1 and 2 | Podologic Grade From 0 to 3France
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedFever, Sweats, and Hot FlashesUnited States
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Obstructive Pulmonary DiseaseChina
-
University Hospital of North NorwayCompleted
-
Shandong Cancer Hospital and InstituteUnknownBreast Neoplasm Female | Radiation Toxicity